Ribupatide

An injectable GLP-1/GIP receptor dual agonist

Ribupatide (KAI-9531) is a once-weekly injectable GLP-1/GIP receptor dual agonist currently being evaluated in a global Phase 3 clinical program for the treatment of obesity. Based on clinical data generated to date, we believe ribupatide has the potential to be a category-leading treatment for people living with obesity.

Leveraging a validated GLP-1-based mechanism and an extensive clinical data set, ribupatide is well-positioned to lead the next era of obesity treatments.

Leveraging a proven mechanism of action that provides substantial weight loss balanced with a favorable tolerability profile, ribupatide is designed to have modified potency on the GLP-1 and GIP receptors and a longer half-life compared to a leading obesity medication, resulting in improved exposure through the full weekly dosing period.

Over 2,500 clinical trial participants have been dosed with ribupatide, including multiple late-stage clinical trials in China by our partner, Hengrui. Treatment with 8 mg ribupatide injection weekly in a randomized, double-blind, placebo-controlled Phase 2 trial conducted in China resulted in 23.6% weight loss from baseline compared to 1.7% for placebo at Week 36 when analyzed using the efficacy estimand with no observed weight loss plateau, indicating further weight loss may be possible with longer treatment duration. The safety and tolerability profile of ribupatide was consistent with the GLP-1-based class of approved therapies.

Based on the results of the clinical program to date, we initiated a global Phase 3 clinical program, named KaiNETIC , to investigate doses up to 10 mg of ribupatide for the treatment of adults with obesity or overweight. Learn more at kaineticstudies.com.